Barclays Retains an Equal Weight Rating on Acadia Healthcare Company, Inc. (ACHC)

Company Overview - Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services in the United States, operating in various settings such as inpatient mental hospitals, specialty treatment facilities, residential treatment programs, and outpatient clinics [4]. Financial Performance - For the fourth quarter of 2025, Acadia reported revenue of $821.5 million, reflecting a 6.1% increase compared to the previous year. Same-facility revenue rose by 4.4%, driven by a 3.1% increase in patient days and a 1.3% rise in revenue per day [3]. - The company experienced a net loss of $13.02 per diluted share, which included a non-cash goodwill impairment charge of $996.2 million. However, adjusted net income was reported at $6.1 million, or $0.07 per share [3]. - Adjusted EBITDA for the quarter was $99.8 million, with a $52.7 million adjustment to professional and general liability reserves [3]. - Acadia increased its licensed beds by 181 in the quarter and by 1,089 throughout 2025. Revenue is projected to range from $3.37 billion to $3.45 billion in 2026, with adjusted EPS expected to be between $1.30 and $1.55 [3]. Analyst Ratings - On March 2, 2026, Barclays analyst Andrew Mok raised Acadia's price target to $20 from $14 while maintaining an Equal Weight rating [2][7]. - Acadia Healthcare was recognized as one of the 12 Best Performing Stocks in February [1].